Overview Dividends

(BBIO) BridgeBio Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US10806X1028

ATTR Medication, FGFR Inhibitor, CaSR Antagonist, Muscular Dystrophy Therapy, Oncology Pipeline

EPS (Earnings per Share)

EPS (Earnings per Share) of BBIO over the last years for every Quarter: "2020-09": -0.98, "2020-12": -1.01, "2021-03": -1.18, "2021-06": -0.66, "2021-09": -1.06, "2021-12": -1.01, "2022-03": -1.19, "2022-06": -0.07, "2022-09": -0.93, "2022-12": -0.92, "2023-03": -0.92, "2023-06": -0.98, "2023-09": -1.08, "2023-12": -0.96, "2024-03": -0.2, "2024-06": -0.39, "2024-09": -0.8596, "2024-12": -1.3744, "2025-03": -0.9888, "2025-06": -0.95, "2025-09": -0.7166,
EPS Growth (3y CAGR): 12.17%
EPS Trend (3y Corr): 3.0%
Last SUE: 0.39σ
Qual. Beats: 0

Revenue

Revenue of BBIO over the last years for every Quarter: 2020-09: 8.127, 2020-12: 0.122, 2021-03: 0.462, 2021-06: 54.024, 2021-09: 2.344, 2021-12: 12.886, 2022-03: 1.694, 2022-06: 73.746, 2022-09: 0.338, 2022-12: 1.87, 2023-03: 1.826, 2023-06: 1.641, 2023-09: 4.091, 2023-12: 1.745, 2024-03: 211.12, 2024-06: 2.168, 2024-09: 2.732, 2024-12: 5.882, 2025-03: 116.633, 2025-06: 110.565, 2025-09: 120.7,
Revenue Growth (3y CAGR): 355.13%
Revenue Trend (3y Corr): 69.8%
Last SUE: 0.19σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 57.2%
Value at Risk 5%th 81.9%
Relative Tail Risk -12.97%
Reward TTM
Sharpe Ratio 2.09
Alpha 159.02
Character TTM
Hurst Exponent 0.209
Beta 1.051
Beta Downside 0.950
Drawdowns 3y
Max DD 49.08%
Mean DD 20.89%
Median DD 20.42%

Description: BBIO BridgeBio Pharma November 04, 2025

BridgeBio Pharma (NASDAQ: BBIO) is a commercial-stage biopharma focused on developing small-molecule and gene-therapy treatments for rare genetic diseases and oncology indications.

Its pipeline includes:

  • Attruby – an oral transthyretin (TTR) stabilizer in late-stage development for ATTR-CM, a progressive amyloidosis affecting the heart.
  • Low-dose infigratinib – an FGFR1-3 selective tyrosine-kinase inhibitor being evaluated in a Phase 3 double-blind trial for achondroplasia and in a Phase 2/3 study for hypochondroplasia.
  • Encaleret – a calcium-sensing-receptor antagonist in Phase 3 for autosomal-dominant hypocalcemia type 1 (ADH1).
  • BBP-418 – a glycosylation-substrate pro-drug in Phase 3 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

BridgeBio also pursues programs in Mendelian genetics, oncology, and gene-therapy platforms, leveraging collaborations with Alexion, Stanford, Leidos Biomedical, and Novartis.

Key recent metrics (as of Q3 2024): market capitalization ≈ $2.3 B, cash and equivalents of $550 M providing ~18 months of runway at current burn, and a 2023-2024 revenue run-rate of $120 M driven primarily by Attruby sales in Europe.

Sector-wide, the rare-disease biotech market is expanding at a CAGR of ~12 % (2022-2027) as payer frameworks increasingly accommodate high-price, high-impact therapies, which underpins BridgeBio’s growth outlook.

For a deeper, data-rich evaluation of BBIO’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.

BBIO Stock Overview

Market Cap in USD 12,538m
Sub-Industry Biotechnology
IPO / Inception 2019-06-27
Return 12m vs S&P 500 158%
Analyst Rating 4.37 of 5

BBIO Dividends

Currently no dividends paid

BBIO Growth Ratios

Metric Value
CAGR 3y 98.64%
CAGR/Max DD Calmar Ratio 2.01
CAGR/Mean DD Pain Ratio 4.72
Current Volume 2103.1k
Average Volume 2126k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-797.1m TTM) > 0 and > 6% of Revenue (6% = 21.2m TTM)
FCFTA -0.59 (>2.0%) and ΔFCFTA 9.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 176.0% (prev 140.2%; Δ 35.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.59 (>3.0%) and CFO -584.8m > Net Income -797.1m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (190.5m) change vs 12m ago 1.06% (target <= -2.0% for YES)
Gross Margin 95.78% (prev 98.90%; Δ -3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 42.54% (prev 32.75%; Δ 9.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -5.63 (EBITDA TTM -677.3m / Interest Expense TTM 121.3m) >= 6 (WARN >= 3)

Altman Z'' -14.58

(A) 0.62 = (Total Current Assets 839.4m - Total Current Liabilities 216.6m) / Total Assets 998.2m
(B) -3.63 = Retained Earnings (Balance) -3.63b / Total Assets 998.2m
warn (B) unusual magnitude: -3.63 — check mapping/units
(C) -0.82 = EBIT TTM -682.6m / Avg Total Assets 831.6m
(D) -1.24 = Book Value of Equity -3.63b / Total Liabilities 2.92b
Total Rating: -14.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 50.77

1. Piotroski 1.0pt = -4.0
2. FCF Yield -4.95% = -2.48
3. FCF Margin data missing
4. Debt/Equity -0.00 = -2.50
5. Debt/Ebitda 0.94 = 1.85
7. RoE 46.77% = 2.50
8. Rev. Trend 69.79% = 5.23
9. EPS Trend 3.05% = 0.15

What is the price of BBIO shares?

As of November 19, 2025, the stock is trading at USD 65.59 with a total of 2,103,050 shares traded.
Over the past week, the price has changed by -1.49%, over one month by +16.59%, over three months by +33.80% and over the past year by +193.47%.

Is BBIO a buy, sell or hold?

BridgeBio Pharma has received a consensus analysts rating of 4.37. Therefore, it is recommended to buy BBIO.
  • Strong Buy: 10
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the BBIO price?

Issuer Target Up/Down from current
Wallstreet Target Price 83.6 27.4%
Analysts Target Price 83.6 27.4%
ValueRay Target Price 70.8 8%

BBIO Fundamental Data Overview November 15, 2025

Market Cap USD = 12.54b (12.54b USD * 1.0 USD.USD)
P/S = 35.4391
P/B = 123.6828
Beta = 1.269
Revenue TTM = 353.8m USD
EBIT TTM = -682.6m USD
EBITDA TTM = -677.3m USD
Long Term Debt = 1.85b USD (from longTermDebt, last quarter)
Short Term Debt = 5.29m USD (from shortTermDebt, last quarter)
Debt = 8.72m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -634.2m USD (from netDebt column, last quarter)
Enterprise Value = 11.90b USD (12.54b + Debt 8.72m - CCE 645.9m)
Interest Coverage Ratio = -5.63 (Ebit TTM -682.6m / Interest Expense TTM 121.3m)
FCF Yield = -4.95% (FCF TTM -589.1m / Enterprise Value 11.90b)
FCF Margin = -166.5% (FCF TTM -589.1m / Revenue TTM 353.8m)
Net Margin = -225.3% (Net Income TTM -797.1m / Revenue TTM 353.8m)
Gross Margin = 95.78% ((Revenue TTM 353.8m - Cost of Revenue TTM 14.9m) / Revenue TTM)
Gross Margin QoQ = 94.56% (prev 96.70%)
Tobins Q-Ratio = 11.92 (Enterprise Value 11.90b / Total Assets 998.2m)
Interest Expense / Debt = 134.6% (Interest Expense 11.7m / Debt 8.72m)
Taxrate = 0.83% (-1.54m / -186.5m)
NOPAT = -677.0m (EBIT -682.6m * (1 - 0.83%)) [loss with tax shield]
Current Ratio = 3.88 (Total Current Assets 839.4m / Total Current Liabilities 216.6m)
Debt / Equity = -0.00 (negative equity) (Debt 8.72m / totalStockholderEquity, last quarter -1.92b)
Debt / EBITDA = 0.94 (negative EBITDA) (Net Debt -634.2m / EBITDA -677.3m)
Debt / FCF = 1.08 (negative FCF - burning cash) (Net Debt -634.2m / FCF TTM -589.1m)
Total Stockholder Equity = -1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -79.85% (Net Income -797.1m / Total Assets 998.2m)
RoE = 46.77% (negative equity) (Net Income TTM -797.1m / Total Stockholder Equity -1.70b)
RoCE = -465.3% (out of range, set to none) (EBIT -682.6m / Capital Employed (Equity -1.70b + L.T.Debt 1.85b))
RoIC = -625.6% (out of range, set to none) (NOPAT -677.0m / Invested Capital 108.2m)
WACC = 9.88% (E(12.54b)/V(12.55b) * Re(9.89%) + (debt cost/tax rate unavailable))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.50%
Fair Price DCF = unknown (Cash Flow -589.1m)
EPS Correlation: 3.05 | EPS CAGR: 12.17% | SUE: 0.39 | # QB: 0
Revenue Correlation: 69.79 | Revenue CAGR: 355.1% | SUE: 0.19 | # QB: 0

Additional Sources for BBIO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle